Skip to content
Global Access Atlas

Market access pathways by country

Explore how an innovative medicine moves from approval to patient access.

Selected market

Netherlands

Outpatient medicines normally require GVS inclusion; specialist medicines enter the open package unless placed in the ministerial sluis. Package advice, price agreement, add-on billing and hospital readiness remain separate decisions.

EC/EMA or CBG-MEB
VWS / Horizonscan / applicant
applicant / Zorginstituut / WAR / ACP
Minister of VWS
Zorginstituut / WAR / ACP
8 decision nodes13 cited sources

For education only — not regulatory, pricing or legal advice.

About the content and how to use it